Glioblastoma auxiliary diagnosis and prognostic evaluation kit based on FUCA1gene and use method of kit

A technology for glioblastoma and auxiliary diagnosis, which is applied in the direction of biochemical equipment and methods, microbiological measurement/testing, etc. It can solve the problems of unclear specific mechanism, glioma expression and prognosis indicators, etc. , to achieve the effect of objective patient prognosis, survival time reduction, and objective evaluation

Inactive Publication Date: 2017-12-12
THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, studies have found that in colorectal cancer and breast cancer, FUCA1 affects the growth of tumor cells not through the defect of enzyme function but due to the constitutive expression of FUCA1, but the specific mechanism is still unclear, and its role in glioma The expression and prognostic indications of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glioblastoma auxiliary diagnosis and prognostic evaluation kit based on FUCA1gene and use method of kit
  • Glioblastoma auxiliary diagnosis and prognostic evaluation kit based on FUCA1gene and use method of kit
  • Glioblastoma auxiliary diagnosis and prognostic evaluation kit based on FUCA1gene and use method of kit

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment

[0035] The experimental methods in the following examples are conventional methods unless otherwise specified, and the involved experimental reagents and materials are conventional biochemical reagents and materials unless otherwise specified.

[0036] 1. TCGA database comparison of FUCA1 differential expression in LGG and GBM

[0037] The Cancer Genome Atlas (TCGA) project team was originally composed of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), and developed into A very large data research platform. As one of the earliest tumors studied, low-grade glioma (LGG) and glioblastoma (GBM) have a large number of comprehensive data results. The LGG and GBM data in TCGA come from (https: / / genome-cancer.ucsc.edu), in which LGG included 530 tumor samples, and GBM included 167 samples. The results of FUCA1 gene transcription level are from the RNA-seq results of the Illumina HiSeq sequencing platform. figure 1 It is the expression o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of detection kits, and in particular relates to a glioblastoma auxiliary diagnosis and prognostic evaluation kit based on an FUCA1 gene and use method of the kit. The kit comprises a PCR (Polymerase Chain Reaction) primer pair for amplifying an FUCA1 gene and a PCR primer pair for amplifying a housekeeping gene GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase). According to the kit, the condition that FUCA1 gene has remarkably different transcription expression levels in LGG and GBM for the first time, meanwhile prognosis of a patient suffering from glioblastoma can be easily judged according to expression levels of the FUCA1 gene, and multi-factor regression analysis of Cox confirms that the FUCA1 gene can be used as an index of independent judgment prognosis of the glioblastoma. Namely, by detecting expression of the FUCA1 gene transcription level, the malignancy grade of a glioma patient can be diagnosed, and the prognosis situation of the patient can be predicted.

Description

technical field [0001] The invention belongs to the technical field of detection kits, and in particular relates to a FUCA1 gene-based aided diagnosis and prognosis evaluation kit for glioblastoma and a use method thereof. Background technique [0002] Glioblastoma is the most malignant and most common primary brain tumor, accounting for about 50% of central nervous system tumors. Although a comprehensive program based on surgery combined with radiation and chemotherapy has become a treatment guideline, the prognosis of glioblastoma patients has not been significantly improved, and the average survival time is only 12 to 15 months. Patients with low-grade glioma (LGG) will develop into high-grade glioma (GBM) after a long or short period of time. At present, the commonly used methods to distinguish low-grade gliomas from high-grade gliomas mainly rely on histopathological diagnosis, but the results of pathological diagnosis have certain human factors and are somewhat unreli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/118C12Q2600/158
Inventor 张毅张超奇曹玲刘莎莎刘裕琳何谦益王乐任飞飞沈志博宋梦佳赵启泰
Owner THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap